Viatris Inc. Issues Nationwide Recall For Xanax XR Following Failed Dissolution Quality Standards

Xanax XR 3 mg tablets recalled nationwide by Viatris Inc. due to dissolution failure. Learn how to identify lot #8177156 and check the FDA safety risk.

By: AXL Media

Published: Apr 16, 2026, 5:25 AM EDT

Source: Information for this report was sourced from FOX Local

Pharmaceutical Manufacturer Triggers Urgent Product Withdrawal

A significant nationwide recall has been initiated for Xanax XR, a commonly prescribed medication used to manage anxiety and panic disorders, following a failed quality control assessment. The American pharmaceutical company Viatris Inc. moved to pull the product from the market after internal testing revealed that the medication did not meet established dissolution standards. This failure indicates that the tablets may not break down or release the active ingredient into the bloodstream as intended, potentially compromising the efficacy and safety of the treatment for patients across the country.

Federal Oversight And Classification Of Medical Risk

The U.S. Food and Drug Administration has officially classified this event as a Class II recall, a designation reserved for products that may cause temporary or medically reversible adverse health effects. While the recall was originally initiated by the company last month, the federal agency finalized the classification on April 8. According to the FDA regulatory framework, the probability of serious adverse health consequences is considered remote, yet the failure to meet chemical breakdown standards necessitates the immediate removal of the affected inventory from the supply chain.

Identification Of The Impacted Medication Lot

The scope of the recall is precisely limited to lot #8177156 of Xanax XR, specifically the 3 mg alprazolam extended-release tablets. These products are distributed in 60-count bottles and carry an expiration date of February 28, 2027. While federal regulators have not disclosed the exact number of bottles or individual pills currently in circulation, the nationwide reach of the notice suggests a significant distribution network. Patients are being encouraged to verify the lot numbers on their prescription packaging to ensure their medication is not part of the compromised batch.